Christopher Laudeman

Mr. Christopher Laudeman

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 March 2021 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
MTMichael Tarpley
Michael Tarpley
HOHelen O. Oladapo
Helen O. Oladapo
DSDillon Strepay
Dillon Strepay
TCThomas B. Caligan
Thomas B. Caligan
LCLhoucine Chdid
Lhoucine Chdid
KWKevin Peter Williams
Kevin Peter Williams

28 June 2024 in Molecules
Verified
Journal Article
Open access
PDF file
DRDina Abu Rabe
Dina Abu Rabe
LCLhoucine Chdid
Lhoucine Chdid
DLDavid R. Lamson
David R. Lamson
CLChristopher Laudeman
Christopher Laudeman
MTMichael Tarpley
Michael Tarpley
KWKevin Peter Williams
Kevin Peter Williams
Aberrant activation of hedgehog (Hh) signaling has been implicated in various cancers. Current FDA-approved inhibitors target the seven-transmembrane receptor Smoothened, but resistance to these drugs has been observed. It has been proposed that a more promising strategy to target this pathway is at the GLI1 transcription factor level. GANT61 was the first small molecule identified to directly suppress GLI-mediated activity; however, its development as a potential anti-cancer agent has been hindered by its modest activity and aqueous chemical instability. Our study aimed to identify novel GLI1 inhibitors. JChem searches identified fifty-two compounds similar to GANT61 and its active metabolite, GANT61-D. We combined high-throughput cell-based assays and molecular docking to evaluate these analogs. Five of the fifty-two GANT61 analogs inhibited activity in Hh-responsive C3H10T1/2 and Gli-reporter NIH3T3 cellular assays without cytotoxicity. Two of the GANT61 analogs, BAS 07019774 and Z27610715, reduced Gli1 mRNA expression in C3H10T1/2 cells. Treatment with BAS 07019774 significantly reduced cell viability in Hh-dependent glioblastoma and lung cancer cell lines. Molecular docking indicated that BAS 07019774 is predicted to bind to the ZF4 region of GLI1, potentially interfering with its ability to bind DNA. Our findings show promise in developing more effective and potent GLI inhibitors.

15 March 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
ADAnita Donlic
Anita Donlic
ESEmily G. Swanson
Emily G. Swanson
LCLiang-Yuan Chiu
Liang-Yuan Chiu
SWSarah L. Wicks
Sarah L. Wicks
AJAline Umuhire Juru
Aline Umuhire Juru
AHAmanda Hargrove
Amanda Hargrove
Discoveries of RNA roles in cellular physiology and pathology are raising the need for new tools that modulate the structure and function of these biomolecules, and small molecules are proving useful. In 2017, we curated the R NA-targeted BI oactive liga N d D atabase (R-BIND) and discovered distinguishing physicochemical properties of RNA-targeting ligands, leading us to propose the existence of an “RNA-privileged” chemical space. Biennial updates of the database and the establishment of a website platform ( rbind.chem.duke.edu ) have provided new insights and tools to design small molecules based on the analyzed physicochemical and spatial properties. In this report and R-BIND 2.0 update, we refined the curation approach and ligand classification system as well as conducted analyses of RNA structure elements for the first time to identify new targeting strategies. Specifically, we curated and analyzed RNA target structural motifs to determine properties of small molecules that may confer selectivity for distinct RNA secondary and tertiary structures. Additionally, we collected sequences of target structures and incorporated an RNA Structure Search algorithm into the website that outputs small molecules targeting similar motifs without a priori secondary structure knowledge. Cheminformatic analyses revealed that, despite the 50% increase in small molecule library size, the distinguishing properties of R-BIND ligands remained significantly different to that of proteins and are therefore still relevant to RNA-targeted probe discovery. Combined, we expect these novel insights and website features to enable rational design of RNA-targeted ligands and to serve as a resource and inspiration for a variety of scientists interested in RNA targeting.